€25.00
Your prediction
Agios Pharmaceuticals Inc. Stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 2.460% | 5.932% | 9.649% | -22.840% | 7.759% | -3.846% | -40.019% |
| Iovance Biotherapeutics Inc. | 1.220% | 12.889% | 17.326% | -54.209% | 3.204% | -64.989% | -93.712% |
| United Therapeutics | -0.270% | 1.895% | 2.329% | 16.876% | -4.376% | 70.962% | 181.793% |
| Neurocrine Bioscience | -1.900% | 4.400% | -4.922% | -1.266% | -10.569% | 12.933% | 16.688% |
Comments
News
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle


